Phillip D. Zamore

Co-Founder at Alnylam Pharmaceuticals, Inc.

Phillip D. Zamore

Phillip D. Zamore

Co-Founder at Alnylam Pharmaceuticals, Inc.

Overview
Career Highlights

Voyager Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc.

RelSci Relationships

1497

Number of Boards

5

Relationships
RelSci Relationships are individuals Phillip D. Zamore likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

President at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at REPLIGEN Corp.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Secretary, Chief Legal Officer & Executive Vice President at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Medical Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Phillip D. Zamore
Potential Connections via
Relationship Science
You
Phillip D. Zamore
Co-Founder at Alnylam Pharmaceuticals, Inc.
Education
Ph.D Biochemistry & Molecular Biology

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

Memberships
Fellow
2015 - Current

The National Academy of Inventors® is a member organization comprising U.S. and international universities, and governmental and non-profit research institutes, with over 4,000 individual inventor members and Fellows spanning more than 250 institutions worldwide. The NAI publishes the multidisciplinary journal Technology and Innovation, Journal of the National Academy of Inventors®. Membership with the NAI is available through local university and non-profit research institute chapters only. To join your university or non-profit research institute’s chapter, you must be a member of your institution’s academic community (includes faculty, staff, alumni and affiliates) and have a patent issued from the USPTO. Universities and non-profit research institutes are invited to Establish a Local Chapter of the NAI, to recognize and encourage their community of inventors.

Career History
Founder
2013 - Current

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Co-Founder
2002 - Current

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Gretchen Stone Cook Professor of Biomedical Sciences
Current

UMass Medical School is a school.

Boards & Committees
Member, Advisory Board
Prior

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Director
Tenure Unconfirmed

THE CENTER PROVIDES EARLY CHILDHOOD, TEEN, ADULT, SENIOR ADULT, CULTURAL, EDUCATIONAL, AND COMMUNITY SERVICE PROGRAMS, AS WELL AS HEALTH AND PHYSICAL FITNESS FACILITIES FOR ITS MEMBERS.

Political Donations
$1,000
2012

Representative from Illinois's 11th Congressional District

$2,000
2012

DNC Service Corp. operates a political party. It is an organization which raises fund for the Democratic Party which has been a part of the U.S. political landscape. The company plans the presidential nominating convention, promotes candidates from the local to the national level and sets the party platform. DNC Service was founded in 1848 and is located in Washington, DC.

Investments
Details Hidden

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Phillip D. Zamore. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Phillip D. Zamore's profile does not indicate a business or promotional relationship of any kind between RelSci and Phillip D. Zamore.